Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · IEX Real-Time Price · USD
16.85
-0.29 (-1.69%)
At close: May 7, 2024, 4:00 PM
17.20
+0.35 (2.08%)
After-hours: May 7, 2024, 6:37 PM EDT
Denali Therapeutics Employees
Denali Therapeutics had 445 employees on December 31, 2023. The number of employees increased by 18 or 4.22% compared to the previous year.
Employees
445
Change (1Y)
18
Growth (1Y)
4.22%
Revenue / Employee
$742,766
Profits / Employee
-$326,346
Market Cap
2.40B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 445 | 18 | 4.22% |
Dec 31, 2022 | 427 | 47 | 12.37% |
Dec 31, 2021 | 380 | 89 | 30.58% |
Dec 31, 2020 | 291 | 30 | 11.49% |
Dec 31, 2019 | 261 | 82 | 45.81% |
Dec 31, 2018 | 179 | 49 | 37.69% |
Dec 31, 2017 | 130 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
ICU Medical | 14,000 |
Patterson Companies | 7,600 |
Premier | 2,800 |
Inari Medical | 1,300 |
Indivior | 1,164 |
PTC Therapeutics | 995 |
Twist Bioscience | 919 |
RxSight | 374 |
DNLI News
- 3 hours ago - Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 days ago - Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - GlobeNewsWire
- 2 months ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Denali Therapeutics Announces $500 million Private Placement Equity Financing - GlobeNewsWire
- 3 months ago - Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™ - GlobeNewsWire
- 3 months ago - Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™ - GlobeNewsWire
- 4 months ago - Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases - GlobeNewsWire
- 6 months ago - Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights - GlobeNewsWire